• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by INVO Fertility Inc.

    11/17/25 6:55:17 AM ET
    $IVF
    Medical/Dental Instruments
    Health Care
    Get the next $IVF alert in real time by email
    NT 10-Q 1 formnt10-q.htm NT 10-Q

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 12b-25

     

    Commission File Number: 001-39701

     

    NOTIFICATION OF LATE FILING

     

    ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q
    ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR  

     

    For Period Ended: September 30, 2025

     

    ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q
    ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR
    ☐ Transition Report on Form 11-K  

     

    For the Transition Period Ended: _________________________________

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: _______________________________________

     

    PART I

    REGISTRANT INFORMATION

     

    Full name of registrant INVO Fertility, Inc.
    Former name if applicable  
    Address of principal executive office 5582 Broadcast Court
    City, state and zip code Sarasota, FL 34240

     

     

     

     

     

     

    PART II

    RULE 12b-25 (b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

     

      (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III

    NARRATIVE

     

    State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed time period.

     

    The registrant is unable to file its Quarterly Report on Form 10-Q for the fiscal period ended September 30, 2025 within the prescribed time period because additional time is required to finalize its financial statements to be filed as part of the Form 10-Q. The registrant expects to file the Form 10-Q within the extension period of 5 calendar days.

     

    PART IV

    OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    Steve Shum   (978)   878-9505
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

     

    ☒ Yes ☐ No

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    ☒ Yes ☐ No

     

    If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    Net loss for the three months ending September 30, 2025 is expected to increase by approximately $1 million as compared to three months ending September 30, 2024 primarily due to an approximately $0.9 million noncash loss from debt extinguishment.

     

    -2-

     

     

    INVO Fertility, Inc.

    (Name of Registrant as Specified in Charter)

     

    Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Dated: November 17, 2025   /s/ Steve Shum
      By: Steve Shum
      Title: CEO

     

    -3-

     

    Get the next $IVF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IVF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IVF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Krigsvold Terah Renee claimed ownership of 1 shares (SEC Form 3)

    3 - INVO Fertility, Inc. (0001417926) (Issuer)

    1/13/26 8:03:23 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    Director Szot Matthew K sold $6 worth of shares (4 units at $1.52) and disposed of 3 shares, closing all direct ownership in the company (SEC Form 4)

    4 - INVO Fertility, Inc. (0001417926) (Issuer)

    12/5/25 9:40:32 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Shum Steve

    4 - INVO Fertility, Inc. (0001417926) (Issuer)

    10/3/25 4:05:15 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    $IVF
    SEC Filings

    View All

    SEC Form 424B3 filed by INVO Fertility Inc.

    424B3 - INVO Fertility, Inc. (0001417926) (Filer)

    2/12/26 5:17:05 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by INVO Fertility Inc.

    EFFECT - INVO Fertility, Inc. (0001417926) (Filer)

    2/11/26 12:15:31 AM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by INVO Fertility Inc.

    S-8 - INVO Fertility, Inc. (0001417926) (Filer)

    2/6/26 4:15:27 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    $IVF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    INVO Fertility Announces Patent Issuance for Modified INVOcell® Device

    SARASOTA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced the final issuance of a U.S. patent covering a modified version of its proprietary INVOcell® device. The patent (U.S. Patent No. 12,544,204 B2) became effective on February 10, 2026, providing intellectual property protection on the INVOcell device through 2040. INVOcell is the world's first FDA-cleared intravaginal culture (IVC) system—a patented medical device for assisted reproductive care that allows fertilizatio

    2/11/26 8:30:00 AM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    INVO Fertility Issues Shareholder Letter Highlighting Strengthened Fundamental Position and Strategic Outlook for Growth

    SARASOTA, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today issued a shareholder letter from its Chief Executive Officer, Steve Shum, outlining the Company's strengthened fundamental position and its strategic outlook for continued growth. In the letter, management highlights meaningful progress across operations, acquisitions, and capital structure, positioning INVO Fertility for growth through both organic initiatives and strategic clinic acquisitions. Dear Fellow Shareholders, As

    2/4/26 9:00:00 AM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    INVO Fertility Enters into $7.5 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

    SARASOTA, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- INVO Fertility Inc. ("INVO" or the "Company") (NASDAQ:IVF), a healthcare company focused on the fertility market, today announced it has entered into a warrant inducement agreement with an investor ("Investor") for the immediate exercise of certain outstanding warrants that the Company issued on December 3, 2025 (the "December 2025 Warrants"). Pursuant to a warrant inducement agreement, the Investor has agreed to a reduced exercise price of the outstanding December 2025 Warrants to an amended exercise price of $1.59, and to exercise the outstanding December 2025 Warrants to purchase an aggregate of 4,733,728 shares of the Company's common s

    1/29/26 8:30:00 AM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    $IVF
    Financials

    Live finance-specific insights

    View All

    INVO Fertility Announces 2024 Financial Results with 116% Annual Revenue Growth and Further Improvements in Adjusted EBITDA

    SARASOTA, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics, today announced fourth quarter and full year 2024 financial results. Q4 2024 Financial Highlights (all metrics compared to Q4 2023 unless otherwise noted) Revenue was $1,685,966, an increase of 22% compared to $1,381,754.Consolidated clinic revenue from the Company's INVO Center in Atlanta, Georgia, and fertility clinic in Madison, Wisconsin increased 24% to $1,687,300, compared to $1,362,938.Revenue from

    4/30/25 9:00:49 AM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    $IVF
    Leadership Updates

    Live Leadership Updates

    View All

    INVO Fertility Announces Intent to Acquire Indiana-Based Fertility Clinic "Family Beginnings"

    SARASOTA, Fla. and INDIANAPOLIS, Nov. 28, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced its intent to acquire Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest. The planned acquisition marks INVO's second acquisition after its purchase of Wisconsin Fertility Institute in 2023 and reflects the Company's multi-pronged strategic initiative to build a nationwide network of fertility centers capable of reaching underserved markets an

    11/28/25 1:05:00 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care